Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes ( British Society of Paediatric Endocrinology and Diabetes (BSPED) ) and the Association of British Clinical Diabetologists ( Association of British Clinical Diabetologists (ABCD) )
Methodological detailsexpert consensus, Group assembled by BSPED T1D SIG and ABCD to review the clinical trial data and develop expert consensus guidelines on teplizumab infusions
- Expert consensus
- Group assembled by BSPED T1D SIG and ABCD to review the clinical trial data and develop expert consensus guidelines on teplizumab infusions
Scope
As issued by the authors
Clinical use of teplizumab (monoclonal anti-CD3 antibody) to delay progression from Stage 2 to Stage 3 T1D in the UK
Original publication
Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes ( BSPED ) and the Association of British Clinical Diabetologists ( ABCD ). Diabet Med. Published 29 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →